TP53 and acute myeloid leukemia: We initially tested the concept that inhibition of multiple kinases involved in the cell cycle could be an effective treatment strategy in drug-resistant and TP53-mutated AML by testing TP-0903 in in vitro and in vivo models (23, 24).